Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer

Mak, Kimberley S.; Smith, Angela M.; Eidelman, Alec; Clayman, R.H.; Niemierko, Andrzej; Cheng, Jed Sian; Matthews, Jonathan; Drumm, Michael; Nielsen, Matthew E.; Feldman, Adam S.; Lee, Richard J.; Zietman, Anthony L.; Chen, I‐Chun; Shipley, William U.; Milowsky, Matthew I.; Efstathiou, Jason A.

doi:10.1016/j.ijrobp.2016.08.023

Cited by 122 publications

(64 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, 23 studies, reporting PROMs in 3568 patients, were evaluated using the COSMIN checklist. An overview of studies and PROMs are presented in Table and Table , respectively.…”

Section: Resultsmentioning

confidence: 99%

“…We identified three generic PROMs (EuroQoL five Dimensions [EQ‐5D] , 36‐item short‐form health survey [SF‐36] , World Health Organisation Quality of Life [WHOQOL‐BREF] ), one cancer‐generic PROM (European Organisation for Research and Treatment of Cancer quality‐of‐life, 30 item core questionnaire [EORTC QLQ‐C30] ), seven BC‐specific PROMs including two for all patients with BC (Bladder Cancer Index [BCI] , Functional Assessment of Cancer Therapy‐Bladder [FACT‐Bl] ), three for MIBC (FACT Vanderbilt Cystectomy Index [FACT‐VCI] , EORTC QLQ‐BLM30 , Ileal Orthotopic Neobladder PRO [IONB‐PRO] ), and two for NMIBC (CAVICAVENMI and EORTC QLQ‐NMIBC24 ). Four ad hoc MIBC PROMs were identified, which were developed specifically for the reporting study .…”

Section: Resultsmentioning

confidence: 99%

“…Three generic PROMs were identified in the review, all had limited psychometric properties reported in studies; the EQ‐5D, SF‐36, and WHOQOL‐BREF . All three generic PROMs are established internationally with multiple non‐BC studies contributing normative and psychometric properties data.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluating patient‐reported outcome measures (PROMs) for bladder cancer: a systematic review using the COnsensus‐based Standards for the selection of health Measurement INstruments (COSMIN) checklist

et al. 2018

View full text Add to dashboard Cite

Patient‐reported outcome measures (PROMs) are important tools used to understand patient‐focused outcomes from care. Various PROMs have been developed for patients with bladder cancer (BC), although the disease's heterogeneity makes selection difficult. Accurate measurement of health‐related quality of life (HRQL) can only be achieved if the PROM chosen is ‘fit for purpose’ (i.e. psychometrically sound). Systematic reviews of psychometric properties are useful for selecting the best PROM for a specific purpose. The COnsensus‐based Standards for the selection of health Measurement INstruments (COSMIN) developed a checklist to improve the selection of health measurement instruments as part of a review process. Our aims were to undertake a systematic review, using the COSMIN criteria, to assess the quality of studies that report the psychometric properties of PROMs used with people with BC and determine the psychometric quality of these PROMs. An electronic search of seven databases including PubMed, MEDLINE and EMBASE (PROSPERO reference CRD42016051974) was undertaken to identify English language publications, published between January 1990 and September 2017 that evaluated psychometric properties of PROMs used in BC research. Two researchers independently screened abstracts and selected full‐text papers. Studies were rated on methodological quality using the COSMIN checklist. Overall, 4663 records were screened and 23 studies, reporting outcomes in 3568 patients, were evaluated using the COSMIN checklist. Most PROMs had limited information reported about their psychometric properties. Studies reporting on the Bladder Cancer Index (BCI) and Functional Assessment of Cancer Therapy Vanderbilt Cystectomy Index (FACT‐VCI) provided the most detail and these PROMs could be evaluated on the most COSMIN properties. Based on the available evidence, no existing PROM stands out as the most appropriate to measure HRQL in BC populations. This is due to two factors; (i) the heterogeneity of BC and its treatments (ii) no PROM was evaluated on all COSMIN measurement properties due to a lack of validation studies. We suggest future evaluation of generic, cancer generic and BC‐specific PROMs to better understand their application with BC populations and propose strategies to help clinicians and researchers.

show abstract

“…Overall, 23 studies, reporting PROMs in 3568 patients, were evaluated using the COSMIN checklist. An overview of studies and PROMs are presented in Table and Table , respectively.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating patient‐reported outcome measures (PROMs) for bladder cancer: a systematic review using the COnsensus‐based Standards for the selection of health Measurement INstruments (COSMIN) checklist

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Although limited by small study populations, several reports to date have demonstrated good long-term QoL in patients who pursue trimodal for MIBC. [2850] One contemporary study of patients who underwent trimodal therapy demonstrated statistically significant higher scores of QoL at a median follow-up of 6 years posttreatment on validated QoL surveys when compared to patients who underwent RC although this was not a randomized study. [7] This supports the need to at least discuss the option of trimodal therapy in well-selected patients.…”

Section: Trimodal Therapymentioning

confidence: 99%

Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?

et al. 2017

View full text Add to dashboard Cite

Introduction:In 2017, neoadjuvant, cisplatin-based chemotherapy followed by radical cystectomy (RC) is considered the gold standard therapy for muscle-invasive bladder based on randomized controlled trials. Across all tumor stages, this approach has been associated with the highest rates of disease-specific survival. However, RC is one of the most challenging procedures performed by urologic surgeons and carries with it significant risks of complications, hospital readmission, and even a small risk of mortality, in addition to lifestyle changes that can have long-term effects on well-being. For these reasons, bladder-sparing approaches are utilized in some highly selected patients. We reviewed the most recent evidence for bladder-sparing modalities for muscle-invasive urothelial bladder cancer and summarize those findings in this review article.Methods:We performed a PubMed literature review utilizing the key words “bladder preservation,” “trimodal therapy,” “muscle-invasive bladder cancer,” and “partial cystectomy” written in English, dating back to 1990. We excluded case reports.Results:Our search yielded more than 2000 articles which we screened. Some articles were then rejected due to inappropriate topic. In addition, we reviewed the most recent American Urological Association, National Comprehensive Cancer Network (NCCN), and European guidelines on muscle-invasive bladder cancer. We identified fifty relevant articles which are summarized in this text. In some rare instances, recommendations are based on expert opinion.Conclusions:Bladder preservation is often considered for quality of life considerations or in the setting of multiple medical comorbidities, and this remains oncologically appropriate even in 2016 in highly selected patients with muscle-invasive urothelial carcinoma of the bladder.

show abstract

“…A recent retrospective study of 173 patients who underwent TMT at Massachusetts General Hospital [64], or RP at University of North Carolina [109] on multivariate analysis revealed association between TMT treatment and better general quality of life, better bowel function, and better sexual function, while urinary symptoms were similar between the two group of patients (11). …”

mentioning

confidence: 99%

Radical Cystectomy is the best choice for most patients with muscle-invasive bladder cancer? Opinion: No

Mitin

2017

Int. braz j urol.

View full text Add to dashboard Cite

Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer

Cited by 122 publications

References 29 publications

Evaluating patient‐reported outcome measures (PROMs) for bladder cancer: a systematic review using the COnsensus‐based Standards for the selection of health Measurement INstruments (COSMIN) checklist

Evaluating patient‐reported outcome measures (PROMs) for bladder cancer: a systematic review using the COnsensus‐based Standards for the selection of health Measurement INstruments (COSMIN) checklist

Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?

Radical Cystectomy is the best choice for most patients with muscle-invasive bladder cancer? Opinion: No

Contact Info

Product

Resources

About